Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 14.06
(3.23%)
CNY 14.06
(3.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 431.38 Million | 704.32 Million | 735.97 Million | 721.72 Million | 614.19 Million | 1.26 Billion |
| Cost of Revenue | 258.52 Million | 159.62 Million | 205.76 Million | 140.89 Million | 125.72 Million | 182.52 Million |
| Gross Profit | 172.85 Million | 544.69 Million | 530.2 Million | 580.83 Million | 488.46 Million | 1.08 Billion |
| Operating Expenses | 680.36 Million | 631.7 Million | 621.12 Million | 656.26 Million | 924.09 Million | 841.08 Million |
| Selling, General and Administrative Expenses | 272.13 Million | 399.01 Million | 460.63 Million | 478.05 Million | 681.7 Million | 697.92 Million |
| Research and Development Expenses | 161.49 Million | 158.67 Million | 105.67 Million | 143.92 Million | 180.31 Million | 94.89 Million |
| Other Expenses | 246.73 Million | -5.71 Million | -5.42 Million | -13.88 Million | 13.99 Million | -13.4 Million |
| Cost and Expenses | 938.88 Million | 791.33 Million | 826.89 Million | 797.15 Million | 1.04 Billion | 1.02 Billion |
| Operating Income | -507.5 Million | -370.8 Million | 39.1 Million | -574.35 Million | -905.3 Million | -320.32 Million |
| Interest Expense | 125.76 Million | 103.24 Million | 87.92 Million | 59.24 Million | 68.9 Million | 37.81 Million |
| Income Tax Expense | 4.33 Million | -265.02 Thousand | 5.24 Million | 21.06 Million | -6.52 Million | 7.05 Million |
| Earnings before Tax | -511.1 Million | -372.81 Million | 33.67 Million | -588.23 Million | -891.31 Million | -333.72 Million |
| Net Income | -513.87 Million | -370.55 Million | 30.8 Million | -609.42 Million | -884.77 Million | -340.77 Million |
| Earnings Per Share Basic | -0.58 | -0.42 | 0.03 | -0.69 | -1.00 | -0.37 |
| Earnings Per Share Diluted | -0.58 | -0.42 | 0.03 | -0.69 | -1.00 | -0.37 |
| Weighted Average Shares Outstanding | 885.99 Million | 883.24 Million | 883.24 Million | 883.24 Million | 883.24 Million | 917.6 Million |
| Weighted Average Shares Outstanding (Diluted) | 885.99 Million | 883.24 Million | 883.24 Million | 883.24 Million | 883.24 Million | 921.02 Million |
| Gross Margin | 0.40 | 0.77 | 0.72 | 0.80 | 0.80 | 0.86 |
| EBIT Margin | -0.54 | 0.03 | 0.57 | 0.03 | -0.51 | 0.28 |
| Profit Margin | -1.19 | -0.53 | 0.04 | -0.84 | -1.44 | -0.27 |
| EBITDA | -233.61 Million | -114.22 Million | 257.64 Million | -431.77 Million | -721.08 Million | -184.45 Million |
| Earnings Before Tax Margin | -1.18 | -0.53 | 0.05 | -0.80 | -1.47 | -0.25 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 119.5 Million | 102.37 Million | 148.8 Million | 431.38 Million | 29.82 Million | 76.27 Million |
| Cost of Revenue | 49.64 Million | 60.43 Million | 59.4 Million | 218.68 Million | 72 Million | 53.26 Million |
| Gross Profit | 69.86 Million | 41.94 Million | 89.4 Million | 212.69 Million | -42.17 Million | 23.01 Million |
| Operating Expenses | 61.33 Million | 58.56 Million | 68.23 Million | 494.18 Million | 126.3 Million | 114.16 Million |
| Selling, General and Administrative Expenses | 109.07 Million | 45.01 Million | 49.29 Million | - | 1.47 Million | 140.43 Million |
| Research and Development Expenses | 18.41 Million | 18.53 Million | 18.99 Million | - | 43.38 Million | 30.3 Million |
| Other Expenses | -66.16 Million | 4.97 Million | 62.26 Thousand | -3.59 Million | 10.17 Million | -12.25 Million |
| Cost and Expenses | 110.97 Million | 118.99 Million | 127.63 Million | 712.86 Million | 198.3 Million | 167.42 Million |
| Operating Income | -23.51 Million | -16.62 Million | 21.17 Million | -507.5 Million | -344.42 Million | -132.4 Million |
| Interest Expense | 26.27 Million | 26.98 Million | 26.16 Million | 120.46 Million | 32.73 Million | 32.2 Million |
| Income Tax Expense | 1.08 Million | 2.4 Million | 4.75 Million | 4.33 Million | -579.21 Thousand | 2.15 Million |
| Earnings before Tax | -23.77 Million | 5.96 Million | -9.59 Million | -511.1 Million | -334.24 Million | -144.65 Million |
| Net Income | -24.44 Million | 3.74 Million | -14.1 Million | -513.87 Million | -333.32 Million | -146.41 Million |
| Earnings Per Share Basic | -0.03 | 0.00 | -0.02 | - | -0.40 | -0.17 |
| Earnings Per Share Diluted | -0.03 | 0.00 | -0.02 | - | -0.40 | -0.17 |
| Weighted Average Shares Outstanding | 883.24 Million | 883.24 Million | 883.24 Million | 885.99 Million | 835.73 Million | 883.24 Million |
| Weighted Average Shares Outstanding (Diluted) | 883.24 Million | 883.24 Million | 883.24 Million | 885.99 Million | 835.73 Million | 883.24 Million |
| Gross Margin | 0.58 | 0.41 | 0.60 | 0.49 | -1.41 | 0.30 |
| EBIT Margin | 0.02 | 0.16 | 0.13 | - | -5.23 | -1.39 |
| Profit Margin | -0.20 | 0.04 | -0.09 | -1.19 | -11.17 | -1.92 |
| EBITDA | 2.5 Million | 16.11 Million | 19.22 Million | - | -155.97 Million | -105.73 Million |
| Earnings Before Tax Margin | -0.20 | -0.16 | 0.14 | -1.18 | -11.55 | -1.74 |
CING
SUH
9562
CXDO
MRM
KRG